Key result
ESC Congress 2022 highlights push to translate novel cardiac imaging biomarkers into clinical practice.
Why the study?
Cardiac imaging parameters and applications are constantly re-evaluated, highlighting the need to translate imaging technology from research to clinical practice.
Highlights the need for translating new cardiac imaging biomarkers into established clinical practice based on ESC Congress 2022 presentations.
New imaging biomarkers in HF merit prospective validation; leaves open their integration into routine practice.
Cardiac imaging is an ever-evolving area, with imaging parameters and application in constant re-evaluation. This was reflected in many imaging debates and by the increased number of scientific contributions at the European Society of Cardiology Congress in 2022. While clinical trials tried to answer clinical questions related to the performance of different imaging modalities, many high-quality presentations focused on new imaging biomarkers in different scenarios, such as heart failure with preserved ejection fraction, valvular heart disease or long COVID. This highlights the need for the translation of cardiac imaging technology from research interests towards established measures of clinical practice.
No takes yet. Share an insight, caveat, or question.
Püntmann et al. (2023) conducted a review in Cardiac imaging. The ESC Congress 2022 highlighted the need to translate new cardiac imaging biomarkers and technologies from research into established clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: